You are here: Home » Reuters » News
Business Standard

Pfizer, Astellas prostate cancer drug succeeds key trial


By Divya Grover

(Reuters) - Inc and Japan's Astellas Pharma Inc said on Thursday their prostate drug the main goal of a trial testing it for a more common form of the disease.

The drug, Xtandi, is already approved to treat metastatic castration-resistant prostate (CRPC) - where the has spread to other parts of the body - and raked in U.S. sales of $141 million in the second quarter for

An approval to treat non-metastatic CRPC would significantly boost sales of Xtandi, which got access to when it bought Medivation for $14 billion last year. Astellas owns the rights to sell Xtandi outside the United States.

said on Thursday that Xtandi, in combination with an anti-hormone therapy, was statistically significant in improving survival rate in men with non-metastatic CRPC without their spreading, when compared with the standalone anti-hormone therapy.

Patients with CRPC experience progression despite androgen deprivation therapy, a treatment that blocks the production of the hormone.

is pinning its growth on the success and approvals of 15 drugs over the next five years, a list that includes Xtandi and breast drug Ibrance.

Earlier this month, the U.S. Food and Drug Administration approved Pfizer's Mylotarg for certain patients with acute myeloid leukemia, re-clearing a drug that had been pulled off the market in 2010.

Prostate a big market for drugmakers. More than 161,000 men are estimated to be diagnosed with prostate in 2017 in the United States, according to the American Society.

Pfizer's shares rose 1.4 percent to $35.55 in light premarket trading.

(Reporting by Divya Grover and Tamara Mathias in Bengaluru; Editing by Savio D'Souza and Saumyadeb Chakrabarty)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Thu, September 14 2017. 20:24 IST